Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck

NCT00095927 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT00095927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00095927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2003
Completion date
June 30, 2008
Enrollment
58 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapeutic agent toxicity, head and neck cancer, mucositis, radiation toxicity, xerostomia